Trials / Recruiting
RecruitingNCT06413615
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of FDA022-BB05 in Patients with Advanced/Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of FDA022-BB05 for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2 overexpressing/expressing solid tumors which are not eligible for curative therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FDA022-BB05 | Monoclonal antibody-drug conjugate for injection |
Timeline
- Start date
- 2024-05-13
- Primary completion
- 2025-07-31
- Completion
- 2026-06-30
- First posted
- 2024-05-14
- Last updated
- 2024-09-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06413615. Inclusion in this directory is not an endorsement.